Manufacturer Supply with High Purity and Stable Quality
Chemical Name: 5-(2-Fluorophenyl)pyrrole-3-Carboxaldehyde
CAS: 881674-56-2
High Quality, Commercialized Production
| Chemical Name |
5-(2-Fluorophenyl)-1H-Pyrrole-3-Carbaldehyde |
| Synonyms |
Vonoprazan Fumarate (TAK-438) Intermediate 3 |
| CAS Number |
881674-56-2 |
| CAT Number |
RF-PI330 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C11H8FNO |
| Molecular Weight |
189.19 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
Yellow to Brown Powder |
| Melting Point |
122.0~131.0℃ |
| Identification: RT(HPLC) |
Conform With The Reference Standard |
| Loss On Drying |
≤0.50% |
| Residue On Ignition |
≤0.50% |
| Related Substances |
|
| Purity |
≥99.0% |
| Any Single Impurity |
≤0.50% |
| Total Impurities |
≤1.0% |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Vonoprazan Fumarate (TAK-438) (CAS 881681-01-2) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
5-(2-Fluorophenyl)-1H-Pyrrole-3-Carbaldehyde (CAS 881674-56-2) acts as a reagent in the synthetic preparation of novel pyrrole derivatives as potassium-competitive acid blocker (P-CAB). 5-(2-Fluorophenyl)pyrrole-3-Carboxaldehyde is the intermediate of Vonoprazan Fumarate (CAS 1260141-27-2). Vonoprazan fumarate (Takecab®), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.